Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Calliditas Therapeutics Ab ADR (CALT)

Calliditas Therapeutics Ab ADR (CALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 611,589
  • Shares Outstanding, K 29,790
  • Annual Sales, $ 113,810 K
  • Annual Income, $ -43,960 K
  • 60-Month Beta 1.50
  • Price/Sales 5.63
  • Price/Cash Flow N/A
  • Price/Book 21.23
Trade CALT with:

Options Overview Details

View History
  • Implied Volatility 97.95% ( -10.78%)
  • Historical Volatility 54.15%
  • IV Percentile 80%
  • IV Rank 63.82%
  • IV High 123.77% on 03/19/24
  • IV Low 52.41% on 07/20/23
  • Put/Call Vol Ratio 32.00
  • Today's Volume 33
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 1.41
  • Today's Open Interest 623
  • Open Int (30-Day) 637

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.20
  • Prior Year -0.67
  • Growth Rate Est. (year over year) +79.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.00 unch
on 04/12/24
23.19 -18.07%
on 03/13/24
-3.07 (-13.91%)
since 03/12/24
3-Month
19.00 unch
on 04/12/24
24.60 -22.76%
on 01/16/24
-6.00 (-24.00%)
since 01/12/24
52-Week
15.25 +24.59%
on 11/13/23
29.30 -35.15%
on 12/26/23
-6.16 (-24.48%)
since 04/12/23

Most Recent Stories

More News
Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a...

CALT : 19.00 (-7.45%)
European Medicines Agency Committee for Orphan Medicinal Products provides positive opinion on Calliditas' application for setanaxib in Alport syndrome

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the European Medicines Agency (EMA)...

CALT : 19.00 (-7.45%)
Everest Medicines' Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

/PRNewswire/ -- Everest Medicines' (HKEX 1952.HK, "Everest", or the "Company") partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)...

CALT : 19.00 (-7.45%)
Calliditas announces filing with UK MHRA for Kinpeygo in IgA nephropathy

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announced that its partner STADA Arzneimittel AG ("STADA") has...

CALT : 19.00 (-7.45%)
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced the presentations of new biomarker and...

CALT : 19.00 (-7.45%)
STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU

Request submitted by STADA to EMA to convert conditional marketing authorization to standard marketing authorization for Kinpeygo treatment for primary IgA...

CALT : 19.00 (-7.45%)
Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the US Food and Drug Administration...

CALT : 19.00 (-7.45%)
Why Shares of Calliditas Therapeutics Are Rising Thursday

The company's shares rose in response to a competitors' mixed phase 3 trial.

CALT : 19.00 (-7.45%)
Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations from the...

CALT : 19.00 (-7.45%)
Everest Medicines Announces Partner Calliditas Therapeutics Receives FDA Priority Review for Full Approval of Nefecon® for the Treatment of IgA Nephropathy

/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced today that U.S. Food and Drug Administration (FDA) has accepted the...

CALT : 19.00 (-7.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Calliditas Therapeutics AB is a specialty pharmaceutical company. It is focused on developing pharmaceutical products for patients with a significant unmet medical need. The compnay's lead candidate consist Nefecon. Calliditas Therapeutics AB is based in Stockholm, Sweden.

See More

Key Turning Points

3rd Resistance Point 20.33
2nd Resistance Point 20.07
1st Resistance Point 19.53
Last Price 19.00
1st Support Level 18.73
2nd Support Level 18.47
3rd Support Level 17.93

See More

52-Week High 29.30
Fibonacci 61.8% 23.93
Fibonacci 50% 22.27
Fibonacci 38.2% 20.62
Last Price 19.00
52-Week Low 15.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar